We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Treatment with an oral lysophosphatidic acid receptor 1 ...
– Systemic sclerosis (SSc) is a rare disease that impacts up to 75,000 people in the United States – – Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous tocilizumab to curb the rate of progressive loss of lung function among adults ...
– Systemic sclerosis (SSc) is a rare disease that impacts up to 75,000 people in the United States – – Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a ...
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD. The Food and Drug Administration (FDA) has approved ...
– Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threatening – – In a global ...
Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback